Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis
Article 2025 en
Authors
AA
April W. Armstrong
ML
Mark Lebwohl
AA
Akihiko Asahina
Abstract
1 min read
Treatment with tildrakizumab was effective with no safety signals found in either of the patient subgroups. Patients with late-onset psoriasis were more likely to achieve complete or near-complete clearance than patients with early-onset psoriasis.
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
Giampiero Girolomoni, Christopher Em Griffiths, James G. Krueger, Frank O. Nestlé, Jean‐François Nicolas, JC Prinz, L. Puig, Mona Ståhle, P.C.M. van de Kerkhof, Matthieu Allez, Paul Emery, C. Paul
Discussion(0)
No comments yet. Be the first to comment.